The US Food and Drug Administration approved 18 generic drugs made by Ranbaxy Laboratories even as the US investigated whether the company fabricated data to get its medicines cleared.
The FDA has been aware of the allegations for at least 18 months, the House Energy and Commerce Committee said in a document on its Web site.
Ranbaxy, India's largest drugmaker, has brought to market nine of the 18 drugs, among them copies of Bristol-Myers Squibb Co's cholesterol drug Pravachol and Johnson & Johnson's nonprescription allergy pill Zyrtec, according to the company.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app